UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   93-4225266
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

400 Crossing Blvd  
Bridgewater, New Jersey   08807
(Address of principal executive offices)   (Zip code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of each exchange on which

each class is to be registered

Class A Common Stock, par value $0.01 per share   The Nasdaq Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates:

Not applicable

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 


EXPLANATORY NOTE

Amneal Pharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement on Form 8-A in connection with the transfer of the listing of its Class A Common Stock, par value $0.01 per share (the “Common Stock”), from the New York Stock Exchange (the “NYSE”) to The Nasdaq Stock Market LLC (“Nasdaq”). The Registrant expects the listing and trading of its Common Stock on the NYSE to cease at the close of trading on December 26, 2023 and that trading will begin on Nasdaq at market open on December 27, 2023.

Item 1. Description of Registrant’s Securities to be Registered

The description of the Registrant’s Common Stock included in Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38485), filed with the Securities and Exchange Commission on November 8, 2023, is incorporated herein by reference, except that any reference to the NYSE is hereby amended to refer to Nasdaq.

Item 2. Exhibits

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on Nasdaq and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.


SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Date: December 26, 2023  

 

  Amneal Pharmaceuticals, Inc.
    By:   /s/ Anastasios Konidaris
      Name: Anastasios Konidaris
     

Title: Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)


Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Amneal Pharmaceuticals
Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Amneal Pharmaceuticals